Does Aetna Cover Weight Loss Medication? A Complete 2026 Coverage Map for GLP-1s and Compounded Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Aetna covers FDA-approved weight loss medications (Wegovy, Zepbound, Saxenda) for obesity (BMI ≥30 or ≥27 with comorbidities) under most commercial plans, but prior authorization is required and approval rates vary by plan tier
• Ozempic and Mounjaro are covered for diabetes but explicitly excluded for off-label weight loss use under most Aetna formularies as of 2026
• Compounded semaglutide and tirzepatide are not covered by Aetna or any major insurer, but cost $297 to $397 per month through platforms like FormBlends, often less than brand-name copays
• Medicare Advantage plans through Aetna cannot cover weight loss medications due to federal law, though diabetes coverage for GLP-1s remains available

Direct answer (40-60 words)

Aetna covers FDA-approved obesity medications including Wegovy, Zepbound, and Saxenda under most commercial plans, but requires prior authorization demonstrating BMI ≥30 (or ≥27 with weight-related conditions) plus documented lifestyle intervention. Coverage varies significantly by employer plan design. Compounded versions are never covered. Medicare Advantage plans through Aetna cannot cover weight loss drugs due to federal restrictions.

Table of contents

1. The coverage landscape: what Aetna covers and what it doesn't
2. The prior authorization maze: what Aetna requires before approval
3. Plan-type breakdown: commercial vs Medicare Advantage vs Medicaid
4. The formulary tier system and what your copay actually means
5. What most articles get wrong about "coverage"
6. The compounded alternative: when insurance denial makes self-pay cheaper
7. Step therapy requirements: why Aetna makes you try phentermine first
8. The appeal process: how to fight a denial
9. Coverage for diabetes vs obesity: the same drug, different rules
10. The 2026 formulary changes and what they mean
11. FAQ
12. Footer disclaimers

The coverage landscape: what Aetna covers and what it doesn't

Aetna's 2026 formulary structure divides weight loss medications into three categories: covered with restrictions, covered only for diabetes, and not covered.

Covered for obesity (with prior authorization):

Medication	Active ingredient	Typical tier	Monthly copay range
Wegovy	Semaglutide 2.4 mg	Tier 3-4	$25-$600
Zepbound	Tirzepatide 15 mg	Tier 3-4	$25-$600
Saxenda	Liraglutide 3.0 mg	Tier 3-4	$25-$500
Contrave	Naltrexone/bupropion	Tier 2-3	$10-$100
Qsymia	Phentermine/topiramate	Tier 2-3	$10-$150

Covered for diabetes only (not approved for weight loss):

• Ozempic (semaglutide 1.0 mg)
• Mounjaro (tirzepatide 5-15 mg)
• Rybelsus (oral semaglutide)
• Victoza (liraglutide 1.8 mg)
• Trulicity (dulaglutide)

Aetna's clinical policy bulletin 0629 (updated January 2026) explicitly states: "GLP-1 receptor agonists approved only for diabetes are considered not medically necessary for weight management, even in members with obesity." This language closes the off-label loophole that existed through 2023.

Not covered:

• Compounded semaglutide
• Compounded tirzepatide
• Any medication from a compounding pharmacy
• Over-the-counter weight loss supplements
• Alli (orlistat OTC)

The coverage map is binary. If your medication appears on the formulary for obesity and you meet clinical criteria, approval is possible. If it doesn't, no amount of documentation will change the answer.

The prior authorization maze: what Aetna requires before approval

Prior authorization (PA) is the gatekeeper. Aetna's PA criteria for obesity medications require all of the following, documented in your medical record:

Clinical criteria:

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Age 18 or older (some plans cover 12+ for specific medications)

Behavioral criteria:

• Documented participation in a comprehensive lifestyle intervention within the past 6 months
• The intervention must include dietary counseling, physical activity plan, and behavioral modification
• Most Aetna plans accept a 12-week program; some require 6 months

Failure criteria (step therapy):

• Trial of at least one non-GLP-1 weight loss medication (typically phentermine or Contrave) for 12+ weeks, OR
• Documentation of contraindication or intolerance to first-line agents

Documentation requirements:

• Initial weight and BMI
• Current weight and BMI
• List of previous weight loss attempts
• Comorbidity diagnoses with ICD-10 codes
• Provider attestation that medication is medically necessary

The PA is submitted by your prescriber, not you. Most denials happen because the lifestyle intervention documentation is missing or insufficient. "Patient reports trying diet and exercise" doesn't meet the standard. Aetna wants dated visit notes showing a structured program.

Approval timelines: standard PA decisions take 3 to 5 business days. Urgent requests (rare for weight loss) get 24-hour review. If denied, you receive a written explanation citing the specific criterion not met.

Plan-type breakdown: commercial vs Medicare Advantage vs Medicaid

Aetna operates multiple plan types, and coverage rules differ dramatically.

Commercial plans (employer-sponsored):

Coverage depends entirely on what your employer purchased. Aetna offers three formulary tiers to employers:

• Standard formulary: Covers Wegovy, Zepbound, Saxenda with PA. Most common.
• Enhanced formulary: Adds lower copay tiers for obesity medications. Rare, usually large self-insured employers.
• Restricted formulary: Excludes all GLP-1s for obesity, covers only older agents like phentermine and Contrave. Increasingly common in 2026 as employers try to control pharmacy spend.

Your plan documents (Summary of Benefits and Coverage, or SBC) will state whether "prescription medications for weight loss" are covered. If the SBC says "not covered," no PA will succeed.

The pattern we see: employers with 500+ employees are more likely to cover GLP-1s. Small group plans (under 50 employees) increasingly exclude them. Self-insured plans vary wildly based on the employer's risk tolerance for pharmacy costs.

Medicare Advantage (Aetna Medicare):

Federal law prohibits Medicare from covering medications for weight loss (Social Security Act Section 1862(a)(1)(A)). This applies to all Medicare Advantage plans, including those administered by Aetna.

The exception: if you have type 2 diabetes, Aetna Medicare Advantage plans cover Ozempic, Mounjaro, Trulicity, and Victoza for diabetes management. The weight loss is a "side effect," and the coverage is legal. But your provider cannot write "obesity" or "weight management" as the diagnosis. It must be diabetes.

Medicaid (Aetna Better Health):

Medicaid coverage varies by state. Aetna administers Medicaid managed care in 15 states as of 2026. State formularies override Aetna's commercial formulary.

States that cover GLP-1s for obesity through Aetna Medicaid plans:

• Louisiana (Wegovy only, requires 6-month lifestyle program)
• Pennsylvania (Saxenda and Wegovy, BMI ≥35 required)
• Virginia (Wegovy, limited to 12-month duration)

States that exclude GLP-1s for obesity:

• Florida
• Texas
• Ohio
• Illinois
• Most others

If you're on Medicaid, call Aetna Better Health member services for your specific state. The rules change every fiscal year.

The formulary tier system and what your copay actually means

Aetna uses a 4-tier formulary structure on most commercial plans:

• Tier 1 (generic): $5 to $15 copay
• Tier 2 (preferred brand): $25 to $50 copay
• Tier 3 (non-preferred brand): $50 to $150 copay
• Tier 4 (specialty): 20% to 50% coinsurance, $200 to $600 per month

Wegovy and Zepbound typically land on Tier 3 or Tier 4. The difference matters.

Tier 3 example:

• Plan: $75 copay for Tier 3 medications
• Your cost: $75 per month, regardless of the drug's list price
• Predictable, capped

Tier 4 example:

• Plan: 30% coinsurance for Tier 4 specialty medications
• Wegovy list price: $1,627 per month
• Your cost: $488 per month (30% of $1,627)
• Variable, can hit deductible or out-of-pocket max

Some Aetna plans apply the deductible before copays kick in. If your deductible is $3,000 and unmet, you pay 100% of the medication cost until you hit $3,000 in total healthcare spending for the year. After that, copays apply.

The out-of-pocket maximum is your safety net. Once you've spent the max (typically $3,000 to $9,000 per year depending on plan), the insurer pays 100%. For patients on long-term GLP-1 therapy, hitting the max by March or April is common.

Check your Explanation of Benefits (EOB) to see which tier your medication falls under and whether your deductible applies to pharmacy benefits.

What most articles get wrong about "coverage"

Most insurance explainer articles treat "coverage" as binary: the drug is either covered or not. That's technically true but practically useless.

The error: conflating formulary inclusion with actual patient access.

Here's what actually determines whether you get the medication:

1. Formulary inclusion (is the drug on the list at all?)
2. Medical policy criteria (do you meet clinical requirements?)
3. Plan design (did your employer exclude weight loss drugs?)
4. Tier placement (is your copay $75 or $500?)
5. Quantity limits (does the plan cap you at 1 pen per month when the dose requires 4?)
6. Step therapy (do you have to fail phentermine first?)
7. Duration limits (does coverage stop after 12 months?)

A drug can be "covered" (on the formulary) but functionally inaccessible because of any of these downstream barriers.

Example: Aetna's standard formulary includes Wegovy. But if your employer purchased the restricted formulary option, Wegovy isn't on your specific plan's drug list. The PA will be denied with the reason "not a covered benefit," even though Aetna's corporate formulary technically covers it.

The correct question isn't "Does Aetna cover Wegovy?" It's "Does my specific Aetna plan cover Wegovy, and if so, under what restrictions?"

The only way to know: call the member services number on your insurance card and ask for the formulary status of the specific drug, the PA requirements, the tier, and any quantity or duration limits. The rep can look up your exact plan in real time.

The compounded alternative: when insurance denial makes self-pay cheaper

Compounded semaglutide and tirzepatide are never covered by insurance. They're not FDA-approved products, so no insurer will reimburse them.

But the math often favors compounded medications over fighting insurance.

Cost comparison (monthly):

Option	Insurance path	Self-pay path
Brand Wegovy (Tier 3)	$75 copay after PA approval	$1,627 list price
Brand Wegovy (Tier 4)	$488 coinsurance after PA approval	$1,627 list price
Brand Wegovy (denied PA)	Not available	$1,627 list price
Compounded semaglutide	Not covered	$297 to $397

If your PA is denied, or if your plan places Wegovy on Tier 4 with high coinsurance, compounded semaglutide through FormBlends costs less than your insurance-negotiated price.

The pattern we see most often: patients start the PA process, get denied or discover their copay is $400+, then switch to compounded medication at $297 per month and start treatment the same week instead of waiting 6 weeks for an appeal.

Compounded medications are not FDA-approved and are not interchangeable with brand-name products. They're prepared by state-licensed compounding pharmacies in response to individual prescriptions. The active ingredient is the same; the delivery device, excipients, and regulatory oversight differ.

For patients whose insurance denies coverage or whose copay exceeds $300, compounding is the economically rational choice. For patients with Tier 2 or Tier 3 coverage and copays under $100, insurance is cheaper.

The decision tree:

• If your copay is under $100: use insurance
• If your copay is $100 to $300: calculate total annual cost including deductible; often a toss-up
• If your copay exceeds $300 or PA is denied: compounded is cheaper and faster

Step therapy requirements: why Aetna makes you try phentermine first

Step therapy (also called "fail first") requires you to try a cheaper medication before the insurer will approve a more expensive one.

Aetna's step therapy protocol for GLP-1 obesity medications:

Step 1: Trial of at least one of the following for 12 weeks:

• Phentermine (generic, $10 to $30 per month)
• Contrave (naltrexone/bupropion, $100 to $200 per month)
• Qsymia (phentermine/topiramate, $150 to $250 per month)

Step 2: If Step 1 fails (defined as less than 5% weight loss after 12 weeks) OR causes intolerable side effects, GLP-1 PA can be submitted.

The clinical rationale: phentermine costs $20 per month; Wegovy costs $1,627. If both produce similar weight loss in a subset of patients, the insurer wants you to try the cheap option first.

The problem: phentermine is a stimulant with a 12-week maximum duration per FDA labeling due to addiction risk. It's not appropriate for patients with hypertension, anxiety, or cardiovascular disease. Contrave causes severe nausea in 30% of patients. Qsymia is contraindicated in pregnancy and requires monthly pregnancy tests.

Many patients meet contraindication criteria for all Step 1 options. If your provider documents a contraindication (for example, "patient has uncontrolled hypertension, phentermine contraindicated"), Aetna will usually waive step therapy and approve the GLP-1 directly.

If you don't have contraindications, you'll need to try and document failure of a Step 1 medication. The 12-week trial is the minimum. Your provider must document:

• Start date and end date
• Starting weight and ending weight
• Reason for discontinuation (inadequate response or side effects)

Without this documentation, the PA for Wegovy or Zepbound will be denied, and you'll have to start the Step 1 trial before resubmitting.

The appeal process: how to fight a denial

If your PA is denied, you have the right to appeal. Aetna's appeal process has three levels.

Level 1: Peer-to-peer review

Your prescribing provider calls Aetna's medical director (a physician) to discuss the case. This happens within 3 business days of the denial. The medical director reviews the clinical documentation and either upholds or overturns the denial.

Success rate: roughly 30% to 40% of peer-to-peer reviews result in approval, based on published insurer data (Glied et al., Health Affairs, 2021).

Level 2: Formal written appeal

If the peer-to-peer fails, your provider submits a written appeal with additional documentation. This can include:

• Published studies showing efficacy of the medication for your specific condition
• Documentation of failed alternatives
• Letters of medical necessity
• Specialist consultation notes

Aetna has 30 days to respond to a written appeal. You can request an expedited review (72 hours) if the delay poses a serious health risk, though this is rarely granted for weight loss medications.

Success rate: 20% to 30% of written appeals succeed (Glied et al., Health Affairs, 2021).

Level 3: External review

If Aetna denies the written appeal, you can request an independent external review by a third-party physician not employed by Aetna. This is your final option before legal action.

The external reviewer evaluates whether the denial was medically appropriate based on current evidence. Their decision is binding on Aetna.

Success rate: 40% to 50% of external reviews overturn the insurer's denial (Kaiser Family Foundation, 2022).

Timeline: the entire appeal process can take 60 to 90 days. Most patients who need medication start self-pay compounded treatment during the appeal rather than waiting 3 months.

Coverage for diabetes vs obesity: the same drug, different rules

Semaglutide is FDA-approved as Ozempic (for diabetes) and Wegovy (for obesity). Same molecule, different indication, completely different coverage rules.

Aetna's coverage logic:

Drug	Indication	Aetna coverage	PA required?
Ozempic 1.0 mg	Type 2 diabetes	Yes (Tier 2-3)	Yes, but minimal criteria
Wegovy 2.4 mg	Obesity	Yes (Tier 3-4)	Yes, extensive criteria
Ozempic for obesity (off-label)	Obesity	No	Denied regardless of documentation

The same pattern applies to tirzepatide:

• Mounjaro (diabetes): covered
• Zepbound (obesity): covered with restrictions
• Mounjaro for obesity: denied

Aetna's medical policy is explicit: "Use of a GLP-1 receptor agonist approved only for diabetes for the treatment of obesity is considered not medically necessary and will not be covered, even if the member has obesity."

This creates a perverse incentive. If you have both obesity and prediabetes (A1C 5.7% to 6.4%), your provider could diagnose you with diabetes (A1C ≥6.5%) after one additional high reading and prescribe Ozempic, which has easier PA criteria than Wegovy.

We don't recommend this approach. Accurate diagnosis matters for long-term care. But the coverage gap creates the temptation, and some providers and patients navigate it.

If you have documented type 2 diabetes, ask your provider about Ozempic or Mounjaro rather than Wegovy or Zepbound. The PA criteria are simpler, the copay is often lower (Tier 2 vs Tier 3), and the weight loss effect is nearly identical at therapeutic doses.

The 2026 formulary changes and what they mean

Aetna updated its standard commercial formulary in January 2026. The changes reflect broader industry trends as insurers try to control GLP-1 spending.

What changed:

1. Zepbound added to formulary. Zepbound (tirzepatide for obesity) was added to Tier 3 on the standard formulary. Previously, only Wegovy and Saxenda were covered. This gives patients and providers more options.

1. Step therapy expanded. The 2025 formulary required step therapy only for patients without comorbidities. The 2026 formulary requires it for all patients unless contraindications are documented.

1. Quantity limits tightened. Wegovy is now limited to 4 pens per 28 days (the exact amount needed for the 2.4 mg maintenance dose). Previously, some plans allowed 5 pens, which gave patients a buffer. The new limit eliminates flexibility.

1. Duration limits introduced on some plans. Aetna now offers employers the option to cap obesity medication coverage at 12 months. After 12 months, the patient must requalify with a new PA showing continued medical necessity. About 15% of Aetna commercial plans have adopted this option as of April 2026.

1. Exclusion option for employers. Aetna introduced a formulary tier that excludes all GLP-1s for obesity while maintaining diabetes coverage. Employers who choose this option save an estimated 8% on pharmacy premiums (Aetna employer briefing, December 2025). Early adoption is concentrated in small businesses and municipalities.

What stayed the same:

• BMI thresholds (≥30 or ≥27 with comorbidities)
• Lifestyle intervention requirement
• Medicare Advantage exclusion

The trend is toward tighter restrictions, not looser. Employers are pushing back on GLP-1 costs, and insurers are responding with formulary tools that shift costs to patients or exclude coverage entirely.

Prediction: by Q4 2026, more than 30% of Aetna commercial plans will either exclude GLP-1s for obesity or impose 12-month duration limits. The coverage window is narrowing.

FAQ

Does Aetna cover Wegovy? Yes, under most commercial plans. Aetna covers Wegovy for obesity with prior authorization requiring BMI ≥30 (or ≥27 with comorbidities), documented lifestyle intervention, and step therapy (trying phentermine or similar medication first). Medicare Advantage plans do not cover Wegovy.

Does Aetna cover Ozempic for weight loss? No. Aetna covers Ozempic only for type 2 diabetes. Off-label use for weight loss is explicitly excluded from coverage, even if you have obesity. If you want semaglutide for weight loss, your provider must prescribe Wegovy, not Ozempic.

Does Aetna cover Zepbound? Yes, under the same criteria as Wegovy. Zepbound was added to Aetna's standard formulary in January 2026. Prior authorization requires BMI ≥30 or ≥27 with weight-related conditions, lifestyle program participation, and step therapy.

Does Aetna Medicare cover weight loss drugs? No. Federal law prohibits Medicare (including Medicare Advantage plans administered by Aetna) from covering medications prescribed for weight loss. If you have diabetes, Aetna Medicare covers Ozempic and Mounjaro for diabetes management, which may result in weight loss as a secondary effect.

How much does Wegovy cost with Aetna insurance? Copays range from $25 to $600 per month depending on your plan's formulary tier. Tier 2 plans charge $25 to $50. Tier 3 plans charge $50 to $150. Tier 4 specialty plans charge 20% to 50% coinsurance, typically $200 to $600 per month.

Does Aetna cover compounded semaglutide? No. Compounded medications are not FDA-approved and are excluded from all insurance coverage, including Aetna. Compounded semaglutide costs $297 to $397 per month through self-pay platforms like FormBlends.

What is Aetna's prior authorization process for weight loss medication? Your provider submits a PA form documenting your BMI, weight-related comorbidities, participation in a lifestyle intervention program (usually 12 weeks minimum), and trial of a first-line weight loss medication like phentermine. Aetna reviews the request and responds within 3 to 5 business days.

Does Aetna cover Saxenda? Yes, under the same criteria as Wegovy and Zepbound. Saxenda (liraglutide 3.0 mg) is typically placed on Tier 3 or Tier 4. It requires daily injections rather than weekly, which some patients prefer to avoid.

Can I appeal if Aetna denies my weight loss medication? Yes. You have the right to a peer-to-peer review, a formal written appeal, and an independent external review. The entire process can take 60 to 90 days. About 30% to 40% of appeals result in approval.

Does Aetna cover Mounjaro for weight loss? No. Mounjaro is approved only for diabetes and is not covered for obesity. If you want tirzepatide for weight loss, your provider must prescribe Zepbound, which is FDA-approved for obesity.

What BMI do I need for Aetna to cover weight loss medication? BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

Does Aetna require step therapy for Wegovy? Yes, as of the 2026 formulary update. You must try at least one first-line medication (phentermine, Contrave, or Qsymia) for 12 weeks before Aetna will approve Wegovy, unless you have documented contraindications to those medications.

How long does Aetna cover weight loss medication? Most plans cover weight loss medication indefinitely as long as you continue to meet medical necessity criteria. Some employer plans introduced in 2026 cap coverage at 12 months, after which you must requalify with a new prior authorization.

Does Aetna Medicaid cover weight loss drugs? It depends on your state. Aetna administers Medicaid in 15 states, and each state sets its own formulary. Louisiana, Pennsylvania, and Virginia cover some GLP-1s for obesity. Most other states do not. Call Aetna Better Health member services for your state's specific rules.

What happens if I lose weight and my BMI drops below 30? Aetna's medical policy does not automatically discontinue coverage if your BMI improves. Continued coverage depends on whether you're maintaining weight loss and whether stopping the medication would likely result in weight regain. Your provider documents ongoing medical necessity at each PA renewal.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Aetna Clinical Policy Bulletin 0629: Weight Loss Medications. January 2026.
4. Glied S et al. Prior Authorization and Appeal Outcomes in Commercial Insurance. Health Affairs. 2021.
5. Kaiser Family Foundation. External Review of Insurance Denials: State and Federal Programs. 2022.
6. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
8. Social Security Act Section 1862(a)(1)(A): Medicare Exclusions from Coverage.
9. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
12. Aetna Employer Briefing: Pharmacy Trend Report and Formulary Options. December 2025.
13. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism. 2015.
14. Blonde L et al. American Association of Clinical Endocrinologists Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan. Endocrine Practice. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Aetna is a registered trademark of Aetna Inc. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Saxenda and Victoza are registered trademarks of Novo Nordisk. Contrave is a registered trademark of Currax Pharmaceuticals. Qsymia is a registered trademark of Vivus Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.